MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    Efficacy of Continuous Subcutaneous Levodopa/Carbidopa Infusion (ND0612) on Motor Signs of PD and Experiences of Daily Living

    O. Rascol, S. Isaacson, P. Lewitt, W. Poewe, J. Ferreira, N. Lopes, S. Sopromadze, J. Pereira, C. Olanow (Toulouse, France)

    Objective: Evaluate the effect of investigational ND0612 on motor signs of PD and motor experiences of daily living (m-EDL), as assessed using the MDS-UPDRS. Background:…
  • 2024 International Congress

    Exploring the Neuroprotective Effects of Diurnal Light Exposure in Early-Stage Parkinson’s Disease: A Longitudinal, Multi-Sensory Intervention Study

    S. Putri, R. Fajar, E. Syafruddin (Gresik, Indonesia)

    Objective: This study aims to explore the neuroprotective effects of controlled diurnal light exposure on neurodegeneration rates in early-stage PD patients, positing that light therapy…
  • 2024 International Congress

    Selecting an Imaging Biomarker for a Multi-Arm Multi-Stage Trial of Disease-Modifying Treatments for Parkinson’s: The EJS ACT-PD Experience

    C. Gonzalez-Robles, S. Al-Bachari, M. Bartlett, R. Petty, S. Collins, R. Ellis-Doyle, G. Mills, P. Piccini, K. Pushparatnam, C. Siu, Z. Walker, M-L. Zeissler, C. Carroll, T. Foltynie, R. Weil, A. Schrag, C. Lambert (London, United Kingdom)

    Objective: To report on the selection of an imaging biomarker for a sub-study in a multi-arm, multi-stage (MAMS) platform trial for disease-modifying therapies (DMTs) in…
  • 2024 International Congress

    PD-DigiCare: Enhancing referral decision-making for advanced treatment in Parkinson’s Disease through objective measurements and patient reported outcomes – a multicenter randomized controlled trial.

    N. Karottki, T. Hørmann Thomsen, P. Jennum, M. Blaabjerg, B. Biering-Sørensen (Glostrup, Denmark)

    Objective: The overall aim is to compare the efficacy of using wearable devices versus standard of care in improving the timeliness of referrals to evaluation…
  • 2024 International Congress

    Effect of Prasinezumab on Parkinson’s Disease Motor Progression in a Long-term Open-label Extension of the PASADENA Trial

    G. Pagano, A. Monnet, A. Reyes, B. Ribba, H. Svoboda, T. Kustermann, T. Simuni, R. Postuma, N. Pavese, F. Stocchi, K. Brockmann, K. Smigorski, V. Gerbaldo, P. Fontoura, R. Doody, G. Kerchner, P. Brundin, K. Marek, A. Bonni, T. Nikolcheva (Basel, Switzerland)

    Objective: To evaluate the long-term effect of prasinezumab on motor progression, assessed as change in MDS-UPDRS Part III in OFF- and ON-state, and MDS-UPDRS Part…
  • 2024 International Congress

    Neurocognitive Functioning (NF) in a Patient with Idiopathic Parkinson’s Disease without Dementia (IPDWD). Subjected to Deep Brain Stimulation (DBS) and Treatment by Clinical, Functional and Advanced Neuropsychology.

    C A. Hurtado-Gonzalez, J F. Ayala-Rico, S. Ospina-Otalvaro, P A. Lenis, J M. Márquez, C O. Moreno, M. Agudelo, S. Guerrero (Cali, Colombia)

    Objective: To identify the Neurocognitive Functioning (NF) in a patient with IPDWD and intervened by DBS, and to analyze the impact of functional neurorehabilitation (FNR)…
  • 2024 International Congress

    Blautia argi ameliorates the motor impairment of 6-Hydroxydopamine hydrochloride-induced Parkinson’s disease rat model

    G. Tian, R. Zhou, J. Lu, W. Shi, R. Li, X. Guo (Xi'an, China)

    Objective: To evaluate the potential protective effects of Blautia argi on a 6-Hydroxydopamine (6-OHDA)-induced rat model of Parkinson's disease (PD). Background: PD is a common…
  • 2024 International Congress

    A Quantitative Investigation has Revealed Nifedipine as a Possible Pharmacological Modulator in Parkinson’s Disease

    G. Kuanar, C. Mahapatra (Cuttack, India)

    Objective: Parkinson's Disease (PD) is strongly linked to atypical electrical firing patterns in the neuronal cells of the globus pallidus externus (GPe), hence highlighting the…
  • 2024 International Congress

    Baseline Variables Associated with Apomorphine Sublingual Film Retention

    J. Kassubek, J. Schwarz, L. López Manzanares, M. Fonseca, C. Denecke Muhr (Ulm, Germany)

    Objective: The aim of this analysis was to identify the baseline variables that differ between patients who completed Study CTH-301 and those who discontinued during…
  • 2024 International Congress

    Opicapone real-world experience in early motor fluctuations: 3-months analysis of the REONPARK study.

    L. Lopez Manzanares, J. Garcia Caldentey, R. Garcia-Ramos, M. Cerdan Sanchez, B. Solano Vila, G. Castilla-Fernandez, I. Pijuan Jimenez, I. Tegel Ayuela (Madrid, Spain)

    Objective: The REONPARK study aims to evaluate COMT inhibitor (iCOMT) effectiveness and tolerability in alleviating motor complications associated with L-dopa treatment in Parkinson’s Disease patients…
  • « Previous Page
  • 1
  • …
  • 50
  • 51
  • 52
  • 53
  • 54
  • …
  • 181
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #24970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley